These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
268 related articles for article (PubMed ID: 29064732)
61. Worldwide epidemiology of neutralizing antibodies to adeno-associated viruses. Calcedo R; Vandenberghe LH; Gao G; Lin J; Wilson JM J Infect Dis; 2009 Feb; 199(3):381-90. PubMed ID: 19133809 [TBL] [Abstract][Full Text] [Related]
62. Efficacy of gene delivery to the brain using AAV and ultrasound depends on serotypes and brain areas. Kofoed RH; Dibia CL; Noseworthy K; Xhima K; Vacaresse N; Hynynen K; Aubert I J Control Release; 2022 Nov; 351():667-680. PubMed ID: 36179767 [TBL] [Abstract][Full Text] [Related]
63. Neutralizing antibodies against adeno-associated viruses in Sjögren's patients: implications for gene therapy. Corden A; Handelman B; Yin H; Cotrim A; Alevizos I; Chiorini JA Gene Ther; 2017 Apr; 24(4):241-244. PubMed ID: 28150697 [TBL] [Abstract][Full Text] [Related]
64. A Generic Method for Fast and Sensitive Detection of Adeno-Associated Viruses Using Modified AAV Receptor Recombinant Proteins. Cui M; Lu Y; Tang C; Zhang R; Wang J; Si Y; Cheng S; Ding W Molecules; 2019 Nov; 24(21):. PubMed ID: 31684125 [TBL] [Abstract][Full Text] [Related]
65. Prevalence of Adeno-Associated Virus 3 Capsid Binding and Neutralizing Antibodies in Healthy and Hemophilia B Individuals from India. Daniel HD; Kumar S; Kannangai R; Lakshmi KM; Agbandje-Mckenna M; Coleman K; Srivastava A; Srivastava A; Abraham AM Hum Gene Ther; 2021 May; 32(9-10):451-457. PubMed ID: 33207962 [TBL] [Abstract][Full Text] [Related]
66. Neutralizing antibodies against adeno-associated viruses in inflammatory bowel disease patients: implications for gene therapy. van der Marel S; Comijn EM; Verspaget HW; van Deventer S; van den Brink GR; Petry H; Hommes DW; Ferreira V Inflamm Bowel Dis; 2011 Dec; 17(12):2436-42. PubMed ID: 21370319 [TBL] [Abstract][Full Text] [Related]
67. Humoral and cellular capsid-specific immune responses to adeno-associated virus type 1 in randomized healthy donors. Veron P; Leborgne C; Monteilhet V; Boutin S; Martin S; Moullier P; Masurier C J Immunol; 2012 Jun; 188(12):6418-24. PubMed ID: 22593612 [TBL] [Abstract][Full Text] [Related]
69. Improved behavior and neuropathology in the mouse model of Sanfilippo type IIIB disease after adeno-associated virus-mediated gene transfer in the striatum. Cressant A; Desmaris N; Verot L; Bréjot T; Froissart R; Vanier MT; Maire I; Heard JM J Neurosci; 2004 Nov; 24(45):10229-39. PubMed ID: 15537895 [TBL] [Abstract][Full Text] [Related]
70. Anti-AAV Antibodies in AAV Gene Therapy: Current Challenges and Possible Solutions. Weber T Front Immunol; 2021; 12():658399. PubMed ID: 33815421 [TBL] [Abstract][Full Text] [Related]
71. AAV serotype-1 mediates early onset of gene expression in mouse hearts and results in better therapeutic effect. Su H; Huang Y; Takagawa J; Barcena A; Arakawa-Hoyt J; Ye J; Grossman W; Kan YW Gene Ther; 2006 Nov; 13(21):1495-502. PubMed ID: 16775632 [TBL] [Abstract][Full Text] [Related]
72. An Improved Adeno-Associated Virus Vector for Neurological Correction of the Mouse Model of Mucopolysaccharidosis IIIA. Gray AL; O'Leary C; Liao A; Agúndez L; Youshani AS; Gleitz HF; Parker H; Taylor JT; Danos O; Hocquemiller M; Palomar N; Linden RM; Henckaerts E; Holley RJ; Bigger BW Hum Gene Ther; 2019 Sep; 30(9):1052-1066. PubMed ID: 31020862 [TBL] [Abstract][Full Text] [Related]
73. Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy. Schulz M; Levy DI; Petropoulos CJ; Bashirians G; Winburn I; Mahn M; Somanathan S; Cheng SH; Byrne BJ Mol Ther; 2023 Mar; 31(3):616-630. PubMed ID: 36635967 [TBL] [Abstract][Full Text] [Related]